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lioma have demonstrated the feasibility of transferring
the herpes simplex virus thymidine kinase (HSVtk)
gene followed by treatment with the prodrug ganci-
clovir.3,4 Another gene therapy strategy that has been
reported in locoregionally advanced non–small cell
lung cancer involves the induction of apoptosis with the
transfer of the tumor suppressor p53 gene.5
Malignant pleural mesothelioma remains a therapeu-tic problem. Conventional therapy with surgery,
chemotherapy, or radiotherapy has largely been ineffec-
tive in curing the majority of patients.1,2 The advent of
gene therapy offers a novel mode of therapy to treat
malignant pleural mesotheliomas through the transfer
of functional genes. Phase I clinical trials in mesothe-
Objective: Conventional treatment for mesothelioma is largely ineffective.
We therefore evaluated the novel approach of adenoviral gene transfer of the
proapoptotic Bcl-2 family member Bak in mesothelioma cancer cell lines,
which are sensitive and resistant to adenoviral p53.
Methods: Binary adenoviral Bak (Ad/GT-Bak and Ad/GV16) and LacZ
(Ad/GT-LacZ and Ad/GV16) vectors were used for transduction of the
mesothelioma cell lines I-45 (p53 resistant) and REN (p53 sensitive). Protein
levels were determined by Western blotting. Apoptosis was assessed by mor-
phologic changes, caspase-3 cleavage, and fluorescence-activated cell sorter
analysis of subdiploid populations. Cell viability was determined with the
XTT assay. Statistical analysis was performed with analysis of variance and
the Student t test.
Results: High levels of Bak gene transfer were seen after coadministration
of Ad/GT-Bak and Ad/GV16 in both mesothelioma cell lines. Apoptosis was
induced 24 hours after Bak but not LacZ gene transfer ([Bak: I-45, 36%;
REN, 25%] vs [LacZ: I-45, 1%; REN, 3%], P < .05]) in p53-sensitive (REN)
and p53-resistant (I-45) cell lines. Cellular viability was significantly
decreased 48 to 72 hours after Bak gene transfer compared with control vec-
tor in both cell lines (72 hours: Bak I-45, 1.4% ± 1.0%, and Bak REN, 4.7%
± 1%, vs Lac-Z I-45, 83% ± 3%, and Lac-Z REN, 100% ± 1%; P < .05).
Conclusions: Adenovirus-mediated overexpression of the Bak gene induces
apoptosis and decreased cellular viability in p53-sensitive and p53-resistant
mesothelioma cells. These data suggest that the gene transfer of proapoptot-
ic Bcl-2 family members may represent a novel gene therapy strategy to treat
mesothelioma.  (J Thorac Cardiovasc Surg 2001;121:61-7)
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Apoptosis is a conserved pathway in all cells, which,
when activated, leads to cellular death by caspase acti-
vation and subsequent chromosome condensation and
nuclear degradation.6 Many tumor cells have evaded
apoptotic cell death by inactivating p53, which is
believed to be an upstream initiator of apoptosis.7
Replacement of wild-type p53 with gene transfer can
lead to apoptosis in lung cancer cells because this
allows the apoptotic pathway to be restored. Unlike
lung cancer cells, however, many mesothelioma cells
fail to undergo apoptosis after p53 gene transfer. The
reason for this may be due to the fact that mesothe-
lioma cells have a very low rate of p53 mutations, and
therefore gene therapy strategies on the basis of p53
replacement are ineffective because most mesothe-
lioma cells already have functional p53.8 We therefore
decided to evaluate other proapoptotic genes. The Bcl-
2 family is another group of genes important in the reg-
ulation of apoptosis with either proapoptotic (Bax and
Bak) or antiapoptotic (Bcl-2 and Bcl-XL) members.9
We therefore hypothesized that overexpression of the
Bak gene would lead to apoptosis in p53-resistant and
p53-sensitive mesothelioma cells by overwhelming
antiapoptotic Bcl-2 family members (Bcl-2 and Bcl-Xl)
and bypassing upstream p53 resistance. To address this
question, we used a binary adenoviral vector system
containing 2 adenoviral vectors in which one vector,
Ad/GT-Bak, contained the Bak gene under control of
the GT promoter and the GAL4/GV16 fusion protein.10
Bak gene expression could then be induced in target tis-
sues by coadministration of the Ad/GT-Bak vector with
the second adenoviral vector Ad/GV16, which pro-
duced the GAL4/GV16 fusion protein (Fig 1).
We have previously shown that Ad/GT-Bak can
induce apoptosis in p53-sensitive lung cancer cells in a
caspase 3–dependent fashion,11 but we were unsure
whether it could also induce apoptosis in mesothelioma
cells that, unlike lung cancer cells, are mostly p53
resistant. To answer this question, we evaluated two
mesothelioma cell lines, one that was p53 sensitive
(REN, p53 mutant) and one that was p53 resistant 
(I-45, p53 wild-type). Our findings showed that we
were able to induce apoptosis and decreased cell via-
bility in both p53-resistant and p53-sensitive mesothe-
lioma cell lines, suggesting that the induction of apop-
tosis and cell death in mesothelioma with Ad/GT-Bak
may represent a novel treatment.
Material and methods
Cell lines and antibodies. The REN (inflammatory epithe-
lial subtype, p53 mutant) mesothelioma cell line was devel-
oped by one of the authors (W.R.S.) and has been previously
described.4 The I-45 (sarcomatous subtype, p53 wild-type)
cell line was originally provided by Dr Joe Testa of the Fox
Chase Cancer Center in Philadelphia, Pennsylvania. All cells
were maintained in RPMI-1640 supplemented with 10% fetal
bovine serum, 10 mmol/L glutamine, 100 U/mL penicillin,
and 100 µg/mL streptomycin (Life Technologies, Inc, Grand
Island, NY) in a 5% carbon dioxide atmosphere at 37°C. The
following antibodies were used: monoclonal antibody to Bcl-
XL was obtained from Santa Cruz Biotechnology (Santa
Cruz, Calif). The polyclonal antibody to CPP32 (caspase 3)
was purchased from PharMingen (San Diego, Calif). The
polyclonal antibodies raised against Bak, Bax, and β-actin
were bought from Santa Cruz Biotechnology.
Adenovirus production and transduction. Construction
of the Ad/GT-LacZ, Ad/GV16, and Ad/GT-Bak vectors have
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Fig 1. Diagram of binary adenoviral vector Ad/GT-Bak, in which Bak gene expression is controlled by the pres-
ence of Gal4/GV16, requiring coadministration of both vectors to induce Bak gene expression.
been reported previously.10,11 The binary adenoviral vector
system required coadministration of Ad/GT-Bak and
Ad/GV16 (hereafter described as Ad/GT-Bak) or Ad/GT-
LacZ and Ad/GV16 (hereafter described as Ad/GT-LacZ).
The transduction efficiencies of the cell lines were deter-
mined with Ad/GT-LacZ and Ad/GV16. Subsequent experi-
ments used viral titers needed to transduce at least 90% of the
cells (MOI, 2400 viral particles = 1600 viral particles
[Ad/GT-Bak] + 800 viral particles [Ad/GV16]).
Western blot analysis. Total cell lysates were prepared
by lysing cell monolayers in plates with sodium dodecyl-
sulfate–polyacrylamide gel electrophoresis (SDS-PAGE).
Each lane was loaded with 5 µg of cell lysate protein, as
determined by BCA protein assay (Pierce, Rockford, Ill).
Subsequently, proteins were separated under reducing con-
ditions on an SDS polyacrylamide gel. After electrophore-
sis at 20 mA for 2 hours, the proteins in the gels were trans-
ferred to Hybond-ECL membranes (Amersham Corp,
Arlington Heights, Ill). Then the membranes were blocked
with 1% dry milk and 0.1% Tween-20 (Sigma, St Louis,
Mo) and incubated with primary antibodies. The mem-
branes were then incubated with secondary antibody con-
jugated with horseradish peroxidase (Amersham,
Piscataway, NJ). The membranes were developed accord-
ing to the Amersham ECL protocol. Relative quantities of
protein were determined by using a densitometer
(Molecular Dynamics Inc, Sunnyvale, Calif).
Apoptosis analysis. Apoptotic cell death was examined by
assessment of cell morphology after Hoechst staining and
flow cytometric analysis of cells for propidium iodide exclu-
sion 24 to 48 hours after transduction. Specimens were ana-
lyzed in an EPICS Profile II flow cytometer (Coulter Corp,
Hialeah, Fla). Additionally, caspase cleavage was assessed by
means of Western blotting to determine activation of the exe-
cution phase of apoptosis.
Cellular viability analysis. Cells were grown in 96-well
plates in 100 µL volume per well. On the first day, cells were
transduced with Ad/GT-Bak or control vectors. On the sec-
ond day, the cells were incubated with the tetrazolium salt
XTT for 4 to 24 hours, according to the Roche protocol
(Roche Diagnostics, Mannheim, Germany). Viability was
assessed spectrophotometrically on an enzyme-linked
immunosorbent assay (ELISA) plate reader.
Statistical analysis. Data in the figures represent the mean of
3 independent experiments with the SD. Analysis of variance
and the 2-tailed Student t test were used for statistical analysis.
Results
Transduction of mesothelioma cells by Ad/GT-Bak
and Ad/GV16. The mesothelioma cell lines used in these
experiments included cells with null p53 (REN) and
wild-type p53 (I-45) genotypes. The titers used for these
experiments were determined by experiments with
Ad/GT-LacZ, which demonstrated that the binary ade-
noviral vector system achieved over 90% transduction
efficiencies with 2400 viral particles (1600 Ad/GT-Bak
plus 800 Ad/GV16). Only low levels of endogenous Bak
protein were observed in cells treated with phosphate-
buffered saline solution (PBS) or infected with Ad/GT-
LacZ, whereas high levels of Bak protein were seen as
early as 24 hours after transduction with Ad/GT-Bak (Fig
2). The levels of proapoptotic Bax and antiapoptotic Bcl-
XL did not change after viral transduction with either
control or Ad/GT-Bak vectors (Fig 2).
Induction of apoptosis in mesothelioma cells by
Ad/GT-Bak. Transduction of the mesothelioma cell
lines with Ad/GT-Bak induced morphologic changes
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Fig 2. Western blot analysis of the expression of Bak, Bax, and Bcl-XL in cell lysates 24 hours after treatment with
PBS (lanes 1), Ad/GT-LacZ (lanes 2), and Ad/GT-Bak (lanes 3). The expression level of actin was used as a con-
trol.
within 24 hours. Cells treated with Ad/GT-Bak became
shrunken and dense appearing, often detaching from
the cell plates, whereas cells from the other control
groups remained in monolayers with normal morphol-
ogy. Hoechst staining was performed and revealed the
presence of cytoplasmic contraction, membrane bleb-
bing, and the formation of apoptotic bodies in the
Ad/GT-Bak–treated cells (Fig 3). To determine whether
these changes were due to apoptosis, propidium iodide
staining and fluorescence-activated cell sorter analysis
was performed, looking for subdiploid populations. As
Table I shows, Ad/GT-Bak treatment induced apoptosis
in both the p53-sensitive (REN) and p53-resistant (I-
45) cell lines as early as 24 hours after transduction.
Additional evidence for the induction of apoptosis by
Ad-GT-Bak included demonstration of caspase 3 cleav-
age from the inactive proenzyme to the activated 17-kd
fragment, which is associated with onset of the execu-
tion phase of apoptosis (Fig 4). Cleavage of the caspase
3 proenzyme was noted in both mesothelioma cell lines
and was not seen in cells treated with control vector
(Ad/GT-LacZ) or PBS.
Decreased cellular viability in mesothelioma cells
after Ad/GT-Bak. Cellular viability was assessed with
the XTT assay. Transduction of both the p53-sensitive
(REN) and p53-resistant (I-45) mesothelioma cell lines
resulted in marked decrease in cellular viability 48 to
72 hours after infection (Fig 5). The REN (mutant p53)
demonstrated 18% ± 3% viability at 48 hours and 4.7%
± 1% at 72 hours. The I-45 (wild-type p53) cell line
showed only 7.7% ± 2.5% viability at 48 hours and
1.4% ± 1% at 72 hours. Treatment with control vector
resulted in no decreased viability in REN cells but did
note some decrease at 72 hours in I-45 cells 83% ± 3%.
Discussion
Malignant pleural mesothelioma is a tumor that is
unresponsive to standard modalities of cancer treat-
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Fig 3. Hoechst staining of mesothelioma cells 24 hours after treatment with PBS (A), Ad/GT-LacZ (B), or Ad/GT-
Bak (C). Only the cells treated with Ad/GT-Bak showed the presence of cytoplasmic contraction, membrane bleb-
bing, and the formation of apoptotic bodies.
Table I.  Induction of apoptosis in mesothelioma cell lines after Ad/GT-Bak transduction
Apoptosis
Mesothelioma cell line PBS control* Ad/GT-LacZ* Ad/GT-Bak* Adenoviral p53*
I-45 (p53 wild-type) 1% ± 1% 1% ± 1% 36% ± 3%† 5% ± 2%
REN (p53 mutant) 2% ± 1% 3% ± 1% 25% ± 4%† 30% ± 5%†
*Mean of 3 experiments ± SD.
†P < .05 accepted as statistically significant.
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Fig 4. Western blot analysis of the expression of Bak and caspase 3 in cell lysates 24 hours after treatment with
PBS (lanes 1), Ad/GT-LacZ (lanes 2), and Ad/GT-Bak (lanes 3). The expression level of actin was used as a con-
trol.
Fig 5. XTT assessment of cellular viability 24 to 72 hours after transduction of I-45 (A) or REN mesothelioma cells
(B) with PBS, Ad/GT-LacZ, or Ad/GT-Bak.
A
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ment.1,2 Gene therapy offers the opportunity of a new
modality of therapy for this fatal disease. A recently
completed phase I clinical trial in mesothelioma
demonstrated the feasibility of treating malignant
mesothelioma with intrapleural instillation of herpes
simplex virus thymidine kinase (HSVtk).3 In that study
21 patients were treated with minimal toxicity with a
replication-incompetent adenoviral vector containing
the gene encoding HSVtk. Other gene therapy strate-
gies include the induction of apoptosis with the transfer
of the tumor suppressor p53 gene. One recently com-
pleted trial in non–small cell lung cancer demonstrated
clinical responses with adenovirus-mediated overex-
pression of wild-type p53 in patients in whom all con-
ventional treatments had failed.5 It is clear, however,
that not all patients respond to adenoviral p53.
Additionally, preclinical experience with mesothelioma
cell lines have demonstrated p53 resistance in a number
of cell lines. We therefore evaluated the effectiveness of
adenoviral transfer of the proapoptotic Bak gene in
mesothelioma cell lines.
The induction of apoptosis or programmed cell death
reflects a balance between signaling events and mole-
cules that either promote or inhibit apoptosis.6,12 Current
data support the hypothesis that within the Bcl-2 family,
the ratio of death antagonist to agonist determines
whether a cell will respond to apoptotic signals.13 This
hypothesis favors the use of adenoviral vectors because
they are able to induce high levels of gene expression,
which would presumably overwhelm the levels of anti-
apoptotic Bcl-2 members. Our observations support this
hypothesis because Ad/GT-Bak was able to induce apo-
ptosis, even in the presence of high endogenous levels of
antiapoptotic Bcl-XL (Fig 2).
Our previous study demonstrated that adenovirus-
mediated overexpression of Bak could induce apo-
ptosis in p53-sensitive lung cancer cells.11 This study
demonstrated the novel observation that Ad/GT-Bak
could also induce apoptosis in cells that are resistant
to p53. The observation that p53-resistant mesothe-
lioma cell lines are sensitive to Ad/GT-Bak is not
necessarily expected because p53 works in part by
up-regulating Bak and Bax.14,15 It may be that the
very high tissue levels of Bak achieved with adenovi-
ral vectors allows adenoviral Bak gene transfer to be
effective. Additionally, Bak may be acting down-
stream from p53 in the apoptotic cascade, thus allow-
ing it to bypass a genetic blockage further upstream
in the cascade. It is important to note, however, that
even though Bak gene transfer is not p53 dependent,
the process appears caspase dependent because cell
lines that lack functional caspase 3 are resistant to
Parp cleavage and development of subdiploid popu-
lations by fluorescence-activated cell sorter
analysis.11
The increased apoptotic potential of Ad/GT-Bak may
come at a price, however, because we have observed
that Ad/GT-Bak appears less selective than adenoviral
p53 and more likely to induce apoptosis in normal
human bronchial epithelial cells (data not shown).
Clinical strategies to overcome toxicity to normal tis-
sue include tumor selective promoters, such as the
telomerase or DF3 promoter.10,16 Alternatively, as
experience with HSVtk demonstrates, direct intrapleur-
al instillation may allow proportionally more mesothe-
lioma tumor cells to be transduced, thereby minimizing
toxicity to normal tissue.
In summary, we have shown that adenovirus-mediat-
ed overexpression of Bak leads to rapid apoptosis in
mesothelioma cells. This antitumor strategy does not
appear dependent on p53 sensitivity, p53 genetic status,
or level of antiapoptotic Bcl-XL. The lack of selectivi-
ty for normal and cancer cells may require strategies,
such as tumor selective expression or intrapleural local-
ization, to avoid toxicity to normal tissues. Because this
adenovirus-based strategy does not require p53 and
induces apoptosis in p53-resistant tumors, it may ulti-
mately provide a novel gene therapy strategy for
patients with malignant pleural mesothelioma.
We thank S. Russo and K. Hunt for help in the preparation
and review of the article.
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Discussion
Dr Nasser K. Altorki (New York, NY). Dr Swisher, I have
a couple of questions for you. Correct me if I am wrong, but
I had the impression that the bcl-2–mediated apoptotic mech-
anism is also to some extent p53 dependent. Is that not so?
Dr Swisher. You are quite right. p53 appears to induce
apoptosis through a cascade with p53 at the top, inducing
other proapoptotic genes, such as proapoptotic Bcl-2 family
members like Bak, which then induce activated caspases to
dismantle the cell. Our interest in the Bcl-2 family was that
we thought if there were functional problems with p53 up
higher, then perhaps we could induce apoptosis further down
the cascade through the Bcl-2 family and overcome some of
the p53 resistance noted in mesothelioma cells. In fact, we
have previously shown that transduction of lung cancer cells
with adenoviral p53 leads to elevated levels of proapoptotic
Bak and Bax, which may be responsible for the induction of
apoptosis seen after p53 gene transfer.
Dr Altorki. Obviously, this is an impressive piece of work.
How do you envision doing that in a model of mesothelioma?
It seems to me that the delivery may not be quite as simple. 
Dr Swisher. There are obviously 2 problems in translating
adenoviral Bak gene therapy to the clinical arena in mesothe-
lioma. The first problem is the preclinical one, which we have
looked at in this study, and that is how apoptosis in mesothe-
lioma cells is induced. The second problem is how this can be
effective clinically. I agree that one of the biggest problems
with gene transfer in mesothelioma is the difficulty of deliv-
ering the vector to the pleural surface because of the locula-
tions within the hemithorax. Therefore, I would envision
delivering the vector in conjunction with an operation, per-
haps after a pleural pneumonectomy, when the gross disease
and loculations have been removed, to get those residual
small cells that are remaining.
Dr David J. Sugarbaker (Boston, Mass). I have one brief
question that Dr Altorki touched on. With the data now
showing that improved local control of mesothelioma in
human subjects undergoing either pleural pneumonectomy
or other more radical operations, we are beginning to see
systemic metastases, more so than in the past. Can you
speculate as to how you might deliver this system systemi-
cally to affect not just the hemithorax but also a systemic
distribution?
Dr Swisher. One of the problems with adenoviral gene
transfer is trying to target systemic micrometastases. You can
get high levels of expression intratumorally with direct injec-
tion, but it is difficult to get high levels systemically through
the bloodstream. I think there may be potential in the future
to address systemic micrometastases with liposomes. In addi-
tion, some work has been done recently to target these lipo-
somes to cell surface receptors. I notice that an upcoming
presentation in this forum documents high levels of folate
receptors in mesothelioma cells, and one can target the lipo-
somes to these receptors. Theoretically, with a liposomal tar-
geting system, one may be able to address systemic
micrometastases in the future.
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